The European Medicines Agency is working with representatives of EU health technology assessment (HTA) bodies and payers to identify situations where the use of real-world evidence (RWE) might be of interest to all three of them to support their respective decision-making functions.
Once RWE “use cases” that are common to the regulators, HTA bodies and payers are identified, the plan is to...








